Financial Data and Key Metrics Changes - The company's base business grew by 8% two years ago, 7% last year, and 6% in the first half of this year, indicating consistent growth [3] - Strong financial leverage was highlighted with significant growth in EPS due to a beat on both the top line and expense management [3] Business Line Data and Key Metrics Changes - Gilead has a strong presence in three areas: virology, oncology, and inflammation/immunology, with a focus on HIV treatment and prevention, liver diseases, and oncology [2] - The HIV prevention market has seen substantial growth, with the introduction of lenacapavir expected to significantly impact market dynamics [6][9] - Seladelpar, a new treatment for primary biliary cholangitis (PBC), was recently launched and is expected to drive growth in the liver disease segment [35][39] Market Data and Key Metrics Changes - The PrEP market is estimated to be a $3 billion to $3.5 billion market today, with significant growth potential as awareness increases [16][17] - The company anticipates expanding the market for HIV prevention both in the U.S. and globally, particularly with the upcoming PURPOSE II study [8][18] Company Strategy and Development Direction - Gilead is diversifying its business and building a larger portfolio through new product launches and acquisitions, such as the acquisition of seladelpar [3][35] - The company aims to leverage its existing relationships with healthcare providers to enhance the market penetration of new treatments [36] - Gilead is focusing on internal innovation while maintaining a regular cadence of business development activities, targeting smaller acquisitions and partnerships [55][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of the HIV business despite potential headwinds from Part D reform, which may mask growth in the short term [41][42] - The company expects to see overall growth driven by multiple business segments, including oncology and liver diseases, alongside HIV [42][43] - Management highlighted the importance of raising awareness for cell therapies to increase patient access and utilization [51] Other Important Information - The company is making progress in developing next-generation HIV treatment regimens, with several candidates in various phases of clinical development [26][29] - Gilead's cell therapy business is expected to grow significantly, with a focus on expanding access to treatments in the U.S. and internationally [50] Q&A Session Summary Question: What is the current status of the PrEP market? - Management noted that the PrEP market is still in its early stages, with significant growth potential as awareness increases and new products are introduced [16][18] Question: How does Gilead plan to compete in the cell therapy market? - Management emphasized the unique advantages of their cell therapy manufacturing capabilities and the potential for their new BCMA cell therapy to be best-in-class [46][48] Question: What are the expectations for seladelpar in the PBC market? - Management believes seladelpar represents a best-in-class treatment for PBC and sees significant growth potential in this underappreciated market [35][39] Question: How does Gilead view business development moving forward? - Management indicated a shift in focus towards smaller acquisitions and partnerships, reflecting a more mature and diversified portfolio [55][56]

Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 12:20 PM ET Company Participants Daniel O'Day - Charman & CEO Andrew Dickinson - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morg ...

Core Insights - Gilead Sciences is undergoing a transformation to create a more sustainable and diversified portfolio, focusing on growth in HIV and expanding into other therapeutic areas [4][11] - The company has made significant investments in virology, particularly in HIV, and is optimistic about the long-acting treatment market and its potential for growth [5][6] - Gilead's clinical pipeline includes 36 trials in oncology and inflammation, with a focus on innovative therapies and cell therapy advancements [7][9] Group 1: Strategic Focus - The company aims to sustain and grow its HIV business while diversifying into other therapeutic areas [4] - Key investments have been made in virology, particularly with the recent advancements in PrEP, which could reshape the market [5] - Gilead is optimistic about the long-acting treatment market, with various options being explored [6] Group 2: Clinical Pipeline and Development - Gilead currently has 36 clinical stage trials in oncology and inflammation, with a focus on Trodelvy and cell therapies [7][8] - The company is developing a Phase II portfolio in oncology and inflammation, with innovative mechanisms being explored [9][10] - The partnership with Arcellx for multiple myeloma presents a significant opportunity for Gilead [9] Group 3: Financial Performance and Growth - Gilead's base business has shown consistent growth, with an 8% increase two years ago, 7% last year, and over 6% this year [21] - The company achieved a 47% operating margin in the second quarter, reflecting effective cost management and growth strategies [22] - Gilead plans to maintain a strong dividend policy while also exploring opportunities for share repurchases [26] Group 4: Market Expansion and Pricing Strategy - The U.S. PrEP market is estimated to be over $3 billion, with potential growth to $4.5 billion through increased adherence and market penetration [43][44] - Gilead is focused on pricing lenacapavir for PrEP based on its unique market position and efficacy data, rather than comparing it to existing treatments [35] - The company is optimistic about expanding PrEP access globally, leveraging strong clinical data to engage with payers [41][42] Group 5: Oncology Strategy - Gilead's oncology business is now a $3 billion run rate, driven by Trodelvy and cell therapy products [52] - The company is focused on expanding Trodelvy's use in earlier lines of breast cancer and exploring its potential in lung cancer [55][59] - Upcoming data from the Arcellx partnership in multiple myeloma is highly anticipated and could significantly impact Gilead's growth in oncology [63]

Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.Rahway, New Jersey-based Merck just flashed a Death Cross, signaling potential trouble ahead. Foster City, California-based Gilead is basking in a Golden Cross, a sign of bullish momentum.Merck: Treading On Thin IceMerck, known for its diverse lineup of drugs and vaccines, is seeing its stock wobble. Despite a decent climb of 8.72% over the past year, recent technical signals are turnin ...

Sundry Photography When looking at the last few weeks, we can make statements about Gilead Sciences Inc. (NASDAQ:GILD), which we could seldom make in the last few years. Gilead Sciences not only outperformed the market, but we also had a streak of nine up days in a row. Looking at the last three months, Gilead Sciences performed great and especially since the beginning of July 2024, Gilead Sciences started to outperform the S&P 500 (SPY). Data by YCharts My last article about Gilead Sciences was publish ...

Ridofranz/iStock via Getty Images My previous article, “Gilead Sciences: Seriously Undervalued At Peak Pessimism,” caused quite a stir in the comments, particularly from those Seeking Alpha readers who remain pessimistic about Gilead Sciences, Inc.'s (NASDAQ:GILD) business prospects. However, that hasn't stopped the company's stock price from rising more than 23% in less than three months. In this article, I'll present an analysis of the sales of its HIV and oncology franchises, the successes and failur ...

Biotech giant Gilead Sciences, Inc. (GILD) has gained 16.8% in the past three months compared with the industry’s growth of 7.6%. The stock has also outperformed the sector and the S&P 500.The stock’s performance was hit by pipeline setbacks earlier in the year. Nonetheless, this month, Gilead reported better-than-expected second-quarter results and raised its annual earnings guidance. Revenues increased 5% from the year-ago quarter’s level due to high HIV, oncology and liver disease drug sales. Earnings al ...

Gilead Sciences, Inc. (GILD) announced that the FDA has granted accelerated approval to seladelpar for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA), in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.The candidate was approved under the brand name Livdelzi.PBC is a rare, chronic, autoimmune disease of the bile ducts that currently has no cure.PBC affects approximately 130,000 Americans, primarily ...

Gilead Sciences says it uncovered a dangerous drug-counterfeiting operation in which its HIV medications were tampered with and improperly resold before reaching patients.The scheme, allegedly run out of two New York City pharmacies, identified Peter Khaim, a twice-convicted medical fraudster, as the mastermind, according to court documents unsealed this month. The company described Khaim as one of the most brazen and largest manufacturers and sellers of counterfeit Gilead medications in the country.Gilead ...

On Thursday, Gilead Sciences, Inc. GILD reported second-quarter revenue of $6.95 billion, beating the consensus of $6.72 billion.Sales increased 5% year over year primarily due to higher product sales in HIV, Liver Disease, and Oncology. Product sales excluding Veklury increased 6% year-over-year to $6.7 billion.Adjusted EPS was $2.01, up from $1.34 a year ago, beating the consensus of $1.60, primarily driven by lower operating expenses and higher revenues.Also Read: Gilead’s $42.5K Priced HIV Drug Could Be ...